The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
Open accessAbstract
PURPOSE: To compare the renal hemodynamic and tubular effects of celecoxib, a selective inhibitor of cyclooxygenase-2 (COX-2) to those of naproxen, a nonselective inhibitor of cyclooxygenases in salt-depleted subjects. METHODS AND SUBJECTS: Forty subjects were randomized into four parallel groups to receive 200 mg celecoxib twice a day, 400 mg celecoxib twice a day, 500 mg naproxen twice a day, or a placebo for 7 days according to a double-blind study design. Blood pressure, renal hemodynamics, and urinary water and electrolyte excretion were measured before and for 3 hours after drug intake on days 1 and 7. RESULTS: Celecoxib had no effect on systemic blood pressure, but short-term transient decreases in renal blood flow and glomerular filtration rate were found with the highest dose of 400 mg on day 1. On the first day, both celecoxib and naproxen decreased urine output (P < .05) and sodium, lithium, and potassium excretion (P < .01). On day 7, similar effects on water and sodium excretion were observed. During repeated administration, a significant sodium retention occurred during the first 3 days. CONCLUSION: In salt-depleted subjects, selective inhibition of COX-2 causes sodium and potassium retention. This suggests that an increased selectivity for COX-2 does not spare the kidney, at least during salt depletion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Penning, T. D., Talley, J. J., Bertenshaw, S. R., Carter, J. S., Collins, P. W., Docter, S., Graneto, M. J., Lee, L. F., Malecha, J. W., Miyashiro, J. M., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960803q · Cited by 1,965
Needleman, P., Truk, J., Jakschik, B. A., Morrison, A. R., & Lefkowith, J. B. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.000441 · Cited by 1,807
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98774-0 · Cited by 1,789
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.
Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A., & Needleman, P. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44821-6 · Cited by 944
Harris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N., & Breyer, M. D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117620 · Cited by 860
A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein.
O'Banion, M. K., Sadowski, H. B., Winn, V., & Young, D. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54491-4 · Cited by 557
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
Masferrer, J. L., Seibert, K., Zweifel, B., & Needleman, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3917 · Cited by 461
Cited by
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Diclofenac: an update on its mechanism of action and safety profile
Gan, T. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.486301 · Cited by 600
Chan, F. K. L., Hung, L. C. T., Suen, B. Y., Wu, J. C. Y., Lee, K. C., Leung, V. K. S., Hui, A. J., To, K. F., Leung, W. K., Wong, V. W. S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021907 · Cited by 555
Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor
Davies, N. M., McLachlan, A. J., Day, R. O., & Williams, K. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038030-00003 · Cited by 424
Metadata
- Authors
- ROSSAT, J., MAILLARD, M., NUSSBERGER, J., BRUNNER, H., & BURNIER, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1999-07
- Volume
- 66
- Issue
- 1
- Pages
- 76-84
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2042274378
- Cited by
- 318
- References
- 22
- FWCI
- 22.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. https://app.cochat.ai/papers/10.1016/s0009-9236(99)70056-1
- The paper
- ROSSAT, J., MAILLARD, M., NUSSBERGER, J., BRUNNER, H., & BURNIER, M. (1999). Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(99)70056-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
